ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025
Jianpi Yifei Tongluo recipe attenuates inflammation by promoting the expression of interferon regulatory factor 4 in the rat model of chronic obstructive pulmonary disease.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo examine the effects of the Jianpi Yifei Tongluo recipe (, JYTR) on chronic obstructive pulmonary disease (COPD) within an animal model and to elucidate its anti-inflammatory mechanisms.
methodsIn this study, we utilized cigarette smoke (CS) exposure and lipopolysaccharide (LPS)-induced models of COPD in rats to evaluate the effects of the JYTR on airway inflammation. Sprague-Dawley rats were randomly assigned to various groups: control, model, budesonide, synbiotics, and low, medium, and high JYTR. Pulmonary function was gauged using an animal volumetric tracer. Pathological alterations in lung tissue were examined under a light microscope. To ascertain cytokine production, we conducted enzyme-linked immunosorbent assay tests, and we employed Western blotting to measure the expression levels of interferon regulatory factor 4 (IRF4), arginase 1(Arg1), inducible nitric oxide synthase (iNOS), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IKB-α), and P65.
resultsCompared to the control group, rats in the COPD model group exhibited significantly compromised pulmonary function and severe inflammatory pathology in the lungs. Treatment with budesonide, synbiotics, and the JYTR markedly improved pulmonary function and diminished the production of inflammatory cytokines transforming growth factor-beta (TGF-β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These improvements were particularly notable in the budesonide group and the high-dose JYTR group. Additionally, the JYTR increased the expression of IRF4 and upregulated the protein expression of Arg1, while concurrently downregulating the protein expression of iNOS, phosphorylated IKB-α, and phosphorylated P65.
conclusionOur current study reveals that JYTR can mitigate inflammatory lung injury, enhance lung function, and lower levels of inflammatory cytokines induced by CS or LPS exposure in COPD model rats. The mechanism behind its anti-inflammatory effect likely involves the regulation of IRF4 expression and M2 polarization through the nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.